The Medication Affordability and Patent Integrity Act requires pharmaceutical companies to share information consistently between the Food and Drug Administration and the U.S. Patent and Trademark Office when seeking drug approvals and patents. Specifically, companies must certify that data about their drugs submitted to the FDA matches what they told the patent office, and they must share any clinically relevant information with both agencies. The law applies to all new drug applications submitted after its enactment, as well as to future patents on previously approved drugs. If a company fails to comply with these disclosure requirements, the FDA can deny or refuse to approve the drug application, and defendants in patent infringement lawsuits can use non-disclosure as a legal defense. The legislation aims to prevent companies from selectively presenting information to regulators and patent offices in ways that might inflate patent protections or drug approval prospects.